Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases

Antoine Petitcollin (1, 2, 3) , Charlène Brochard (2, 1, 4) , Laurent Siproudhis (2, 4, 1) , Camille Tron (1, 2, 3) , Marie-Clémence Verdier (1, 2, 3) , Florian Lemaitre (1, 2, 3) , Camille Lucidarme (1) , Guillaume Bouguen (1, 2, 4) , Éric Bellissant (1, 2, 3)

1 CHU Pontchaillou [Rennes]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 UR Médecine - Université de Rennes - Faculté de Médecine
4 NuMeCan - Nutrition, Métabolismes et Cancer

Keywords: Population Pharmacokinetics; Real-World Data; De-escalation; Inflammatory Bowel Diseases; Infliximab; Therapeutic Drug Monitoring; Dose tapering

Domains: Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology; Life Sciences [q-bio]; Immunology; Immunotherapy

Antoine Petitcollin, Charlène Brochard, Laurent Siproudhis, Camille Tron, Marie-Clémence Verdier, et al.. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. Clinical Pharmacology and Therapeutics, 2019, 106 (3), pp.605-615. ⟨10.1002/cpt.1429⟩. ⟨hal-02086789⟩